X4 Pharmaceuticals, Inc Cash And Cash Equivalents At Carrying Value

Quick Answer

X4 Pharmaceuticals, Inc reported Cash And Cash Equivalents At Carrying Value of $217.05 million for the year ending 2025.

  • X4 Pharmaceuticals, Inc showed an increase of +289.7% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
  • This data is from X4 Pharmaceuticals, Inc's annual report (Form 10-K), filed with the SEC on March 17, 2026.
  • XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
  • Over the full 10 years of available data (2016 to 2025), X4 Pharmaceuticals, Inc's Cash And Cash Equivalents At Carrying Value has grown by 1,331.7%.
  • Historical annual values: Fiscal year 2025: $217.05 million | Fiscal year 2024: $55.70 million | Fiscal year 2023: $99.22 million | Fiscal year 2022: $121.72 million | Fiscal year 2021: $81.79 million | Fiscal year 2020: $78.71 million | Fiscal year 2019: $126.18 million | Fiscal year 2018: $8.13 million | Fiscal year 2017: $26.68 million | Fiscal year 2016: $15.16 million.
  • Data sourced from SEC EDGAR public filings as of June 23, 2026.

Last verified: